

**NATIONAL INSTITUTE FOR HEALTH AND CARE  
EXCELLENCE**

**HEALTH TECHNOLOGY APPRAISAL PROGRAMME**

**Equality impact assessment – Guidance development**

**STA Osimertinib with pemetrexed and platinum-based  
chemotherapy for untreated EGFR mutation-positive  
advanced non-small-cell lung cancer [ID6328]**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

**Consultation**

- |   |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
| No potential equality issues raised during scoping.   |

- |  |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
| No   |

- |   |
|---|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?  |
| The committee noted that people with an Asian family background were more likely to have EGFR-positive advanced NSCLC. Because its recommendation does not restrict access to treatment for some people over others, the committee agreed this was not an equalities issue. |

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
No

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?
Yes – paragraph 3.17

**Approved by Associate Director (name):** Ian Watson

**Date:** 22 October 2024